HLA-DQA1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The HLA-DQA1 gene encodes the alpha chain of the HLA-DQ heterodimer, a critical MHC class II molecule primarily expressed on antigen-presenting cells (APCs) for presenting peptides to CD4+ T cells, initiating adaptive immune responses. Its extreme polymorphism, particularly in the peptide-binding groove (α1 domain), dictates individual susceptibility to autoimmune diseases like celiac disease (DQ2.5, DQ8) and type 1 diabetes (DQ8, DQ2.5, DQ6 protection).
• HLA-DQ molecules are central to the exogenous antigen presentation pathway, involving endosomal processing, invariant chain (CD74) dissociation facilitated by HLA-DM, and subsequent presentation of peptide antigens to CD4+ T cells, triggering T-cell receptor (TCR) signaling cascades. This process is crucial for both initiating immune responses and for central tolerance during thymic selection.
• Specific HLA-DQ allotypes are strongly associated with distinct clinical conditions, including DQ2.5 and DQ8 with celiac disease due to their preferential binding of deamidated gluten peptides, and DQ6 (DQA1*01:02–DQB1*06:02) with narcolepsy type 1, suggesting autoimmune targeting of hypocretin-producing neurons.
• Viral pathogens like HCMV (US2, US3), HIV (Nef), and KSHV (MIR1/2) have evolved mechanisms to downregulate MHC class II surface expression, including HLA-DQ, to evade CD4+ T-cell recognition and immune surveillance. Bacterial pathogens such as M. tuberculosis and C. trachomatis also interfere with MHC class II antigen presentation pathways.
• Therapeutic strategies targeting HLA-DQ for autoimmune diseases include peptide-based competitive inhibitors (e.g., ZED1227 for celiac disease), small-molecule inhibitors of antigen presentation machinery (e.g., cathepsin S inhibitors), and investigational monoclonal antibodies. Pharmacogenomic associations, such as DQ alleles influencing co-trimoxazole hypersensitivity, highlight the clinical relevance of HLA-DQ in drug response.

Executive Summary & Key Metadata

The HLA-DQA1 gene encodes the alpha chain of the HLA-DQ heterodimeric cell-surface glycoprotein, a classical Major Histocompatibility Complex (MHC) class II molecule. HLA-DQ is expressed primarily on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, where it presents processed peptide antigens (9–20 amino acids) to CD4+ helper T lymphocytes. This presentation is the initiating event for adaptive immune responses, and the extraordinary polymorphism of HLA-DQA1 (and its partner HLA-DQB1) dictates the repertoire of peptides presented, thereby shaping individual immune responsiveness, susceptibility to autoimmune diseases, and outcomes in infectious disease and cancer immunotherapy.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Genomic Architecture

The HLA-DQA1 gene resides on the short arm of chromosome 6 at cytogenetic band 6p21.32, within the class II region of the human Major Histocompatibility Complex (MHC). This region spans approximately 3.6 Mb and is one of the most gene-dense and polymorphic segments of the human genome. The MHC class II region is organized into subregions: DP, DM, DO, DQ, and DR. The DQ subregion contains two pairs of alpha and beta chain genes: HLA-DQA1 and HLA-DQB1 (encoding the classical DQ molecule), and HLA-DQA2 and HLA-DQB2 (encoding the non-classical, poorly expressed DQ2 molecules).

The genomic coordinates for HLA-DQA1 (GRCh38/hg38) are approximately chr6: 32,628,579–32,634,786 (minus strand). The gene spans ~6.2 kb and consists of 5 exons and 4 introns, a structure highly conserved among MHC class II alpha chain genes.

Exon–Intron Structure of HLA-DQA1:

The promoter region of HLA-DQA1 is located ~200 bp upstream of the transcription start site (TSS) and contains the canonical MHC class II promoter elements: the S (W), X, X2, and Y boxes. These cis-acting elements are recognized by a multiprotein enhanceosome complex:

• S box (W box): Binds RFX complex (RFX5, RFXAP, RFXANK) and NF-Y.
• X box: Binds RFX5.
• X2 box: Binds CREB/ATF family transcription factors.
• Y box: Binds NF-Y (a trimeric CCAAT-binding factor).

The master transcriptional regulator of MHC class II genes is CIITA (Class II Major Histocompatibility Complex Transactivator), encoded by the MHC2TA gene on chromosome 16. CIITA does not bind DNA directly but is recruited to the enhanceosome via protein–protein interactions with RFX and NF-Y, subsequently recruiting histone acetyltransferases (e.g., CBP/p300) and chromatin remodeling complexes (SWI/SNF) to establish a permissive chromatin state. CIITA expression is itself regulated by three independent promoters (pI, pIII, pIV), allowing cell-type-specific and cytokine-inducible (IFN-γ) expression.

1.2 Polymorphism and Haplotypic Organization

HLA-DQA1 is among the most polymorphic genes in the human genome, with over 100 known alleles (as of 2024, the IPD-IMGT/HLA Database lists >120 alleles). The vast majority of nucleotide substitutions are non-synonymous and concentrated in exon 2, which encodes the α1 domain that forms half of the peptide-binding groove. This hypervariable region is the primary determinant of peptide-binding specificity and alloreactivity.

The HLA-DQA1 gene is in strong linkage disequilibrium (LD) with HLA-DQB1, and the two genes are inherited as a functional unit (haplotype). Common haplotypes include:

• **DQ2.5 (DQA1*05:01–DQB1*02:01):** Strongly associated with celiac disease.
• **DQ2.2 (DQA1*02:01–DQB1*02:02):** Weakly associated with celiac disease.
• **DQ8 (DQA1*03:01–DQB1*03:02):** Associated with celiac disease and type 1 diabetes.
• **DQ6 (DQA1*01:02–DQB1*06:02):** Protective for type 1 diabetes; associated with narcolepsy.

1.3 Alternative Splicing and Isoforms

While HLA-DQA1 is not known for extensive alternative splicing, several transcript variants have been reported:

• Canonical transcript (NM_002122.5): Encodes the full-length 254-amino-acid preproprotein.
• Soluble HLA-DQA1 (sHLA-DQ): Generated by alternative splicing that skips exon 4 (transmembrane domain), producing a secreted, soluble form of the α chain. Soluble HLA class II molecules are found in serum and can modulate T-cell responses, though their physiological significance remains under investigation.
• Intron-retaining variants: Detected in some tissues, likely subject to nonsense-mediated decay (NMD) and not translated into functional proteins.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The HLA-DQA1 protein (UniProt P01909) is synthesized as a 254-amino-acid precursor with a 23-residue signal peptide (cleaved in the ER lumen). The mature protein (229 aa) is a type I transmembrane glycoprotein with the following domain architecture:

2.2 Quaternary Structure: The HLA-DQ Heterodimer

HLA-DQA1 does not function as a monomer. It assembles non-covalently with the HLA-DQB1 β chain to form the HLA-DQ heterodimer. The α1/β1 domains together form the peptide-binding groove, a structure composed of an eight-stranded β-pleated sheet floor (four strands from α1, four from β1) flanked by two antiparallel α-helices (one from α1, one from β1). The groove is open at both ends, allowing peptides of 9–20 residues to bind in an extended conformation.

Key structural features of the HLA-DQ peptide-binding groove:

• Pockets P1, P4, P6, P7, P9: Five specificity pockets that accommodate peptide side chains. The amino acid composition of these pockets is determined by polymorphic residues in both α1 and β1 domains.
• Conserved hydrogen-bond network: A set of conserved residues (e.g., Asn62α, Asn69α, Gln57β) forms hydrogen bonds with the peptide backbone, anchoring the peptide in a fixed register.
• Dimerization interface: The α2 and β2 Ig-like domains interact extensively, stabilizing the heterodimer. The transmembrane domains also contribute to dimer stability.

2.3 Structural Insights from Crystallography

High-resolution crystal structures of HLA-DQ molecules have been solved, providing atomic-level detail:

• PDB 1JK8: HLA-DQ2.5 (DQA1*05:01/DQB1*02:01) bound to a deamidated gluten peptide (QLQPFPQPELPY). This structure revealed how the DQ2.5 molecule preferentially binds negatively charged peptides (due to the presence of Lys71β and absence of Asp57β), explaining its dominant role in celiac disease.
• PDB 4GG6: HLA-DQ8 (DQA1*03:01/DQB1*03:02) in complex with an insulin-derived peptide, providing insight into type 1 diabetes pathogenesis.
• PDB 1UVQ: HLA-DQ1 (DQA1*01:01/DQB1*05:01) with an influenza hemagglutinin peptide.

These structures demonstrate that the α1 domain contributes primarily to the P1 and P7 pockets, while the β1 domain shapes the P4, P6, and P9 pockets. The polymorphic residues in the α1 domain (e.g., positions 25, 34, 40, 47, 55, 56, 64, 66, 69, 75, 76) are all located in or near the peptide-binding groove, directly influencing peptide repertoire.

2.4 Post-Translational Modifications

• N-linked glycosylation: Asn78 in the α1 domain is a conserved N-glycosylation site (N-X-S/T motif). The glycan is added in the ER and processed in the Golgi; it is not required for peptide binding but contributes to protein stability and intracellular trafficking.
• Disulfide bond: Cys107–Cys163 in the α2 domain is essential for proper folding.
• Phosphorylation: The cytoplasmic tail can be phosphorylated, though the functional significance is not fully defined.

Interactive 3D Protein Visualizer: Load HLA-DQA1 (PDB: 1JK8) Use the interactive viewer to explore the α1/α2 domain architecture, the peptide-binding groove, and the polymorphic residues that define HLA-DQ allotypes. Rotate the molecule, color by B-factor or hydrophobicity, and overlay the bound gluten peptide.

3. Cellular Signaling Pathways & Molecular Function

3.1 The MHC Class II Antigen Presentation Pathway

The primary function of HLA-DQA1 is to participate in the exogenous antigen presentation pathway, which is initiated by the uptake of extracellular proteins into APCs. The pathway proceeds through the following stages:

1. Antigen uptake: APCs internalize extracellular proteins via phagocytosis, macropinocytosis, or receptor-mediated endocytosis.
2. Endosomal processing: Internalized proteins are delivered to early endosomes, which mature into late endosomes and ultimately lysosomes. In these acidic compartments (pH 4.5–5.5), proteases (cathepsins B, D, L, S) degrade the proteins into peptide fragments.
3. MHC class II synthesis and assembly: In the ER, HLA-DQA1 and HLA-DQB1 chains are synthesized and assembled with the invariant chain (CD74, Ii) . The invariant chain trimerizes and binds to the peptide-binding groove, preventing premature loading of ER-resident peptides. It also directs the (αβ-Ii)₃ nonameric complex through the Golgi to the endosomal compartment.
4. CLIP removal: In the MHC class II compartment (MIIC), the invariant chain is sequentially cleaved by cathepsins, leaving a short fragment called CLIP (Class II-associated Invariant chain Peptide) (residues 81–104 of Ii) in the groove. CLIP must be removed for antigenic peptides to bind.
5. HLA-DM-mediated peptide exchange: The non-classical MHC class II molecule HLA-DM (encoded by HLA-DMA and HLA-DMB) catalyzes the release of CLIP and stabilizes the empty MHC class II molecule, facilitating the binding of high-affinity antigenic peptides. HLA-DO (encoded by HLA-DOA and HLA-DOB) can inhibit HLA-DM activity in B cells.
6. Cell-surface expression: The stable peptide-loaded MHC class II molecule is transported to the plasma membrane, where it can be recognized by CD4+ T cells.

3.2 T-Cell Recognition and Signal Transduction

The peptide-MHC class II (pMHCII) complex on the APC surface is recognized by the T-cell receptor (TCR) on CD4+ T cells. The TCR–pMHCII interaction is the first signal in T-cell activation. The CD4 co-receptor binds to a conserved region of the MHC class II β2 domain, stabilizing the interaction and recruiting the Src-family kinase Lck to the TCR signaling complex.

The downstream signaling cascade includes:

1. Lck-mediated phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 ζ chains.
2. ZAP-70 recruitment and activation via SH2 domain binding to phosphorylated ITAMs.
3. Activation of LAT (Linker for Activation of T cells) and SLP-76, leading to the formation of a signaling complex.
4. PLCγ1 activation, which cleaves PIP₂ into IP₃ and DAG, mobilizing intracellular calcium and activating PKCθ.
5. MAPK pathway activation (Ras/Raf/MEK/ERK) and NF-κB and NFAT transcription factor activation, culminating in IL-2 production and T-cell proliferation.

3.3 Thymic Selection and Central Tolerance

In the thymus, HLA-DQ (and other MHC class II molecules) expressed on thymic epithelial cells (TECs) and dendritic cells mediate positive and negative selection of developing T cells:

• Positive selection: CD4+CD8+ double-positive thymocytes whose TCRs can recognize self-pMHCII complexes with low affinity are rescued from apoptosis and differentiate into CD4+ single-positive T cells.
• Negative selection: Thymocytes with high-affinity TCRs for self-pMHCII undergo apoptosis (clonal deletion), eliminating self-reactive T cells. The autoimmune regulator (AIRE) gene drives ectopic expression of tissue-specific antigens in medullary TECs, enabling negative selection against peripheral self-antigens.

3.4 Protein-Protein Interaction Networks

The HLA-DQA1 protein participates in a well-characterized interactome:

3.5 Regulatory Feedback Loops

The expression of HLA-DQA1 is subject to multiple layers of regulation:

• Positive feedback: IFN-γ signaling via JAK1/JAK2–STAT1 activates CIITA promoter IV, increasing MHC class II expression. This amplifies antigen presentation during inflammation.
• Negative regulation: The E3 ubiquitin ligase MARCH1 (Membrane-Associated RING-CH protein 1) ubiquitinates lysine residues in the cytoplasmic tail of MHC class II β chains, promoting endocytosis and lysosomal degradation. MARCH1 expression is downregulated by IL-10 and upregulated by TLR signaling, providing a mechanism for modulating antigen presentation.
• Transcriptional silencing: In plasma cells and some tumors, CIITA expression is silenced by DNA methylation, leading to loss of MHC class II expression and immune evasion.

sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant ER as "Endoplasmic Reticulum"
    participant MIIC as "MHC Class II Compartment"
    participant DM as "HLA-DM"
    participant Tcell as "CD4+ T Cell"
    Note over APC: Uptake of extracellular antigen
    APC->>APC: Endocytosis and proteolytic processing
    ER->>ER: Synthesis of HLA-DQA1 and HLA-DQB1
    ER->>ER: Assembly with invariant chain (CD74)
    ER->>MIIC: Transport via Golgi
    MIIC->>MIIC: Cathepsin cleavage of CD74 to CLIP
    DM->>MIIC: HLA-DM binds to HLA-DQ-CLIP complex
    DM->>MIIC: CLIP removal and peptide loading
    MIIC->>APC: Cell-surface expression of pMHCII
    APC->>Tcell: TCR recognizes pMHCII
    Tcell->>Tcell: Lck/ZAP-70/LAT signaling cascade
    Tcell->>Tcell: IL-2 production and proliferation

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 The Nature of HLA-DQA1 Polymorphism

Unlike typical disease genes where rare, high-penetrance mutations cause monogenic disorders, the clinical significance of HLA-DQA1 lies in its common allelic variation. The "mutations" of clinical relevance are the polymorphic amino acid substitutions that define distinct allotypes, each with different peptide-binding properties. These variants are not pathogenic per se but confer susceptibility or resistance to autoimmune and infectious diseases.

4.2 Key Polymorphic Residues in the α1 Domain

The following positions in the α1 domain are highly polymorphic and contribute to peptide-binding specificity:

4.3 Disease-Associated Alleles and Mechanistic Basis

4.3.1 Celiac Disease

Celiac disease is a gluten-induced enteropathy with one of the strongest known HLA associations. Over 90% of patients carry the HLA-DQ2.5 haplotype (DQA1*05:01–DQB1*02:01), and most of the remainder carry HLA-DQ8 (DQA1*03:01–DQB1*03:02).

Mechanistic basis: Gluten peptides are rich in proline and glutamine, making them resistant to gastrointestinal proteases. Tissue transglutaminase 2 (TG2) deamidates specific glutamine residues to glutamic acid, creating negatively charged peptides. The DQ2.5 molecule has a preference for negatively charged peptides at the P4, P6, and P7 pockets due to the presence of:

• Lys71β (in the β chain) at P4
• Asp57β deletion (the DQB1*02:01 allele lacks Asp57, altering the P9 pocket)
• Arg70α at P7

This unique binding preference allows DQ2.5 to present deamidated gluten peptides (e.g., the immunodominant 33-mer peptide) to CD4+ T cells, driving the pathogenic Th1/Th17 response.

4.3.2 Type 1 Diabetes (T1D)

HLA-DQA1 alleles contribute to T1D susceptibility and resistance:

• Susceptibility: DQA1*03:01 (with DQB1*03:02, forming DQ8) and DQA1*05:01 (with DQB1*02:01, forming DQ2.5) increase risk.
• Protection: DQA1*01:02 (with DQB1*06:02, forming DQ6) is strongly protective (odds ratio < 0.05).

The protective effect of DQ6 is attributed to its ability to present diabetes-related autoantigens (e.g., insulin, GAD65, IA-2) in a manner that promotes regulatory T-cell (Treg) differentiation rather than effector T-cell responses. The DQ8 molecule, by contrast, presents insulin peptides that activate pathogenic CD4+ T cells.

4.3.3 Rheumatoid Arthritis (RA)

The shared epitope (SE) hypothesis links HLA-DRB1 alleles to RA, but HLA-DQA1 also contributes. The DQ haplotypes DQA1*03:01–DQB1*03:02 (DQ8) and DQA1*05:01–DQB1*02:01 (DQ2.5) are associated with anti-citrullinated protein antibody (ACPA)-positive RA, particularly in combination with SE-positive DRB1 alleles. The mechanism involves presentation of citrullinated peptides (e.g., from vimentin, fibrinogen) to autoreactive T cells.

4.3.4 Narcolepsy Type 1

Narcolepsy type 1 is strongly associated with **DQA1*01:02–DQB1*06:02 (DQ6)**. Over 95% of patients carry this haplotype. The mechanism is thought to involve autoimmune destruction of hypocretin-producing neurons in the hypothalamus. The DQ6 molecule likely presents a hypocretin-derived peptide to CD4+ T cells, initiating an autoimmune response. The 2009 H1N1 influenza pandemic (Pandemrix vaccine) triggered a surge in narcolepsy cases, suggesting molecular mimicry between viral and hypocretin peptides.

4.3.5 Multiple Sclerosis (MS)

The primary MS risk allele is **HLA-DRB1*15:01, but the associated haplotype also includes DQA1*01:02–DQB1*06:02**. The DQ6 molecule may contribute to MS pathogenesis by presenting myelin basic protein (MBP) peptides to Th17 cells.

4.4 ClinVar and Pathogenic Variant Classification

Because HLA-DQA1 alleles are common and not "pathogenic" in the Mendelian sense, ClinVar does not classify them as pathogenic/likely pathogenic variants. Instead, the relevant database is the IPD-IMGT/HLA Database, which curates allele sequences and their functional annotations. However, rare loss-of-function variants (e.g., frameshift or nonsense mutations) have been reported:

• Frameshift mutations in exon 2 or 3 that abrogate protein expression would result in a complete lack of HLA-DQ surface expression. Such individuals would have severely impaired CD4+ T-cell responses to exogenous antigens, though they would likely be identified only through immunophenotyping.
• Splice-site mutations affecting exon 4 (transmembrane domain) would produce soluble HLA-DQ molecules, potentially leading to immune dysregulation.

4.5 Clinical Differential Diagnosis

When a patient presents with symptoms suggestive of an HLA-associated disease, the following differentials should be considered:

5. Host-Pathogen & Viral Interactions

5.1 Viral Immune Evasion Targeting MHC Class II

Several viruses have evolved mechanisms to downregulate MHC class II expression, thereby evading CD4+ T-cell responses:

5.1.1 Human Cytomegalovirus (HCMV)

HCMV encodes US2 and US3 glycoproteins that target MHC class II molecules for degradation:

• US2 binds to MHC class II α/β heterodimers in the ER and retrotranslocates them to the cytosol for proteasomal degradation (ER-associated degradation, ERAD).
• US3 retains MHC class II molecules in the ER by binding to the peptide-binding groove, preventing their transport to the MIIC.

5.1.2 Human Immunodeficiency Virus (HIV)

HIV-1 Nef protein downregulates MHC class II surface expression by:

• Binding to the cytoplasmic tail of MHC class II β chains and promoting their endocytosis.
• Redirecting newly synthesized MHC class II molecules from the trans-Golgi network to lysosomes for degradation.

This downregulation impairs CD4+ T-cell help and contributes to immune evasion.

5.1.3 Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)

KSHV encodes MIR1 and MIR2 (modulators of immune recognition), which are E3 ubiquitin ligases that ubiquitinate MHC class II molecules, promoting their internalization and degradation.

5.2 Bacterial Interactions

5.2.1 Mycobacterium tuberculosis

M. tuberculosis survives within macrophages by inhibiting MHC class II antigen presentation. The bacterium:

• Produces lipoarabinomannan (LAM), which inhibits MHC class II gene transcription by blocking CIITA expression.
• Secretes the protein ESAT-6, which downregulates MHC class II surface expression.

5.2.2 Chlamydia trachomatis

C. trachomatis secretes a protease (CPAF) that degrades RFX5, a key transcription factor for MHC class II genes, thereby reducing HLA-DQA1 expression.

5.3 Molecular Mimicry

The association between HLA-DQ alleles and autoimmune diseases often involves molecular mimicry, where microbial peptides resemble self-peptides:

• Narcolepsy and H1N1 influenza: The 2009 pandemic H1N1 virus and the Pandemrix vaccine contained hemagglutinin peptides that mimic hypocretin (orexin) peptides presented by DQ6.
• Celiac disease and adenovirus: The adenovirus type 12 E1B protein contains a peptide (LQNPSYQEL) that shares sequence homology with the gluten peptide QLQPFPQPELPY, potentially triggering celiac disease in genetically susceptible individuals.

5.4 HLA-DQ and Infectious Disease Susceptibility

Certain HLA-DQ alleles influence susceptibility to infectious diseases:

• Hepatitis B virus (HBV): DQA1*01:02–DQB1*06:02 is associated with persistent HBV infection, while DQA1*03:01–DQB1*03:02 is associated with viral clearance.
• Hepatitis C virus (HCV): DQA1*03:01–DQB1*03:02 is associated with spontaneous clearance of HCV.
• **Malaria (Plasmodium falciparum):** DQA1*01:01–DQB1*05:01 is associated with reduced risk of severe malaria.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 HLA-DQ as a Drug Target

HLA-DQ molecules are attractive therapeutic targets for autoimmune diseases. Strategies include:

6.1.1 Peptide-Based Competitive Inhibitors

The most direct approach is to design high-affinity peptides that competitively block the binding of pathogenic autoantigens to HLA-DQ molecules. For celiac disease, several investigational agents are in development:

• ZED1227 (Zedira GmbH): A transglutaminase 2 (TG2) inhibitor that prevents gluten deamidation, thereby reducing the generation of immunogenic peptides. In Phase 2b clinical trials, ZED1227 reduced gluten-induced mucosal damage in celiac patients.
• Nexvax2 (ImmusanT): A peptide-based immunotherapy (epitope-specific immunotherapy, ESIT) containing three modified gluten peptides designed to induce tolerance in HLA-DQ2.5+ celiac patients. Phase 2 trials showed mixed results, with some patients experiencing a "cytokine release syndrome" upon dosing, indicating target engagement.

6.1.2 Monoclonal Antibodies

• Anti-HLA-DQ antibodies: Monoclonal antibodies targeting HLA-DQ have been explored for the treatment of autoimmune diseases and for preventing allograft rejection. However, the ubiquitous expression of HLA-DQ on APCs raises concerns about broad immunosuppression.
• Anti-CD4 antibodies: Agents like ibalizumab (a CD4-specific antibody) indirectly block the CD4–MHC class II interaction, though ibalizumab is primarily used for HIV.

6.1.3 Small-Molecule Inhibitors of Antigen Presentation

• Cathepsin inhibitors: Inhibitors of cathepsin S (e.g., RG7625, VBY-036) block invariant chain processing, preventing CLIP generation and thus inhibiting MHC class II peptide loading. Cathepsin S inhibitors have been investigated for autoimmune diseases (RA, psoriasis) and are in clinical trials.
• HLA-DM modulators: Small molecules that enhance HLA-DM activity could promote the exchange of pathogenic peptides for tolerogenic ones, though no such agents are in clinical development.

6.2 Pharmacogenomic Implications

HLA-DQ alleles influence drug efficacy and toxicity:

6.2.1 Drug Hypersensitivity Reactions

While HLA-B*57:01 is the classic example (abacavir hypersensitivity), HLA-DQ alleles have been implicated in other drug reactions:

• Co-trimoxazole (trimethoprim-sulfamethoxazole): HLA-DQA1*01:02–DQB1*06:02 is associated with an increased risk of severe cutaneous adverse reactions (SCARs) in some populations.
• Allopurinol: HLA-B*58:01 is the primary risk allele, but HLA-DQ variants may modulate the risk.

6.2.2 Vaccine Response Variability

HLA-DQ alleles influence the magnitude and specificity of vaccine-induced antibody responses:

• Hepatitis B vaccine: Non-responders are more likely to carry HLA-DQA1*01:02–DQB1*06:02, while high responders often carry DQA1*03:01–DQB1*03:02.
• Influenza vaccine: HLA-DQ alleles shape the CD4+ T-cell response to hemagglutinin and neuraminidase epitopes.

6.3 Gene Therapy and CRISPR-Based Approaches

• CRISPR-Cas9 knockout of HLA-DQA1: In allogeneic cell therapies (e.g., CAR-T cells), knockout of MHC class II genes (including HLA-DQA1) is being explored to prevent graft-versus-host disease (GvHD) and allorejection. However, complete loss of MHC class II would render cells susceptible to NK-cell killing (due to "missing-self" recognition).
• HLA-edited iPSCs: Induced pluripotent stem cells with edited HLA-DQA1 alleles are being developed to create "universal donor" cells for regenerative medicine.

6.4 Investigational Agents Summary

7. Bioinformatic Resources & Database Accessions

| STRING | Homo sapiens HLA-DQA1 (ENSP00000357183) | https://string

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance